Literatur
- 1
Beer J H.
Prevention of venous thromboembolism in internal medicine patients.
Ther Umsch.
1992;
49
825-832
- 2
Bergqvist D, Agnelli G, Cohen A T, Eldor A, Nilsson P E, Moigne-Amrani A L, Dietrich-Neto F.
for the Enoxacan II investigators .
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery
for cancer.
N Engl J Med.
2002;
346
975-980
- 3
Bernstein C N, Blanchard J F, Houston D S, Wajda A.
The incidence of deep venous thrombosis and pulmonary embolism among patients with
inflammatory bowel disease: a population-based cohort study.
Thromb Haemost.
2001;
85
430-434
- 4 Cohen A T. Fondaparinux versus placebo for venous thromboembolism in medical patients. ISTH
Abstract 2003
- 5
Geerts W H, Pineo G F, Heit J A. et al .
Prevention of venous thromboembolism.
Chest.
2004;
126
338S-400S
- 6
Haas S.
At-Home-Studie: Konsequente Thromboseprophylaxe auch bei bettlägerigen Hausarztpatienten.
Hämostaseologie.
2004;
24
91-93
- 7
Harenberg J, Roebruck P, Heene D L.
Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention
of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group.
Haemostasis.
1996;
26
127-139
- 8
Havig O.
Deep vein thrombosis and pulmonary embolism: An autopsy study with multiple regression
analysis of possible risk factors.
Acta Chirurg Scand.
1977;
478
1-120
- 9
Hills N H, Pflug J J, Jeyasingh K, Boardman L, Calnan J S.
Prevention of deep vein thrombosis by intermittent pneumatic compression of calf.
Br Med J.
1972;
1
131-135
- 10
Kakkar A K.
Thrombosis and cancer.
Hematol J.
2004;
5
S20-S23
(Suppl 3)
- 11
Kleber F X, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach C W. THE-PRINCE
Study Group .
Randomized comparison of enoxaparin with unfractionated heparin for the prevention
of venous thromboembolism in medical patients with heart failure or severe respiratory
disease.
Am Heart J.
2003;
145
614-621
- 12
Lechler E, Schramm W, Flosbach C W.
The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety
profile of a low-molecular-weight heaprin (enoxaparin). The Prime Study Group.
Haemostasis.
1996;
26
49-56
(Suppl 2)
- 13
Leizorovicz A, Cohen A T, Turpie A G. et al .
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism
in acutely ill medical patients.
Circulation.
2004;
110
874-879
- 14
Maurer B J, Wray R, Shillingford J P.
Frequency of venous thrombosis after myocardial infarction.
Lancet.
1971;
2
1385-1387
- 15
Miller R R, Lies J E, Carretta R F. et al .
Prevention of lower extremity venous thrombosis by early mobilization. Confirmation
in patients with acute myocardial infarction by 125I-fibrinogen uptake and venography.
Ann Intern Med.
1976;
84
700-703
- 16
Mismetti P, Laporte-Simitsidis S, Tardy B. et al .
Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight
heparins: a meta-analysis of randomised clinical trials.
Thromb Haemost.
2000;
83
14-19
- 17
Murray T S, Lorimer A R, Cox F C, Lawrie T DV.
Leg-vein thrombosis following myocardial infarction.
Lancet.
1970;
2
792-793ii
- 18
Negus D, Pinto D J, Le Quesne L P, Brown N, Chapman M.
125-I-labelled fibrinogen in the diagnosis of deep-vein thrombosis and its correlation
with phlebography.
Br J Surg.
1968;
55
835-839
- 19
Nicolaides A N, Kakkar V V, Field E S, Fish P.
Optimal electrical stimulus for prevention of deep vein thrombosis.
Br Med J.
1972;
3
756-758
- 20
Nicolaides A N, Breddin H K, Fareed J. et al .
Cardiovascular Disease Educational and Research Trust and the International Union
of Angiology. Prevention of venous thromboembolism. International Consensus Statement.
Guidelines compiled in accordance with the scientific evidence.
Int Angiol.
2001;
20
1-37
- 21
Planes A, Vochelle N, Darmon J Y. et al .
Risk of deep-venous thrombosis after hospital discharge in patients having undergone
total hip replacement: double-blind randomized comparison of Enoxaparin versus placebo.
Lancet.
1996;
348
224-228
- 22
Riedler G F.
Thromboseprophylaxe in der Inneren Medizin.
Therapeutische Umschau.
1977;
34
363-367
- 23
Samama M M, Cohen A T, Darmon J Y. et al .
A comparison or enoxaparin with placebo for the prevention of venous thrombembolism
in acutely ill medical patients.
N Engl J Med.
1999;
341
793-800
- 24
Warkentin T E, Greinacher A.
Heparin-induced thrombocytopenia: Recognition, treatment and prevention.
Chest.
2004;
126
311S-337S
Priv.-Doz. Dr. med. Knut Kröger
Klinik und Poliklinik für Angiologie, Universitätsklinik Essen
Hufelandstraße 55
45122 Essen
Phone: 0201/7232530
Fax: 0201/7235967
Email: knut.kroeger@uni-essen.de
